Evaluation of prognostic factor for anaplastic thyroid carcinoma

Abstract

Anaplastic thyroid carcinoma （ATC） is an aggressive disease with poor prognosis. There are few reports on long-term survival by multimodal therapy. We report 21 cases of ATC treated in the Saitama Medical University International Medical Center from 2007 to 2015. Prognostic Index （PI）, inflammatory biomarkers, immune checkpoint molecule, and whether radical surgery was performed or not were evaluated.
The median survival time （MST） was 15.4 months in the radical surgery group, but was 2.6 months in the non-surgery group, showing a significant difference （p＜0.001）.
Of the 11 ATC patients, PD-L1 expression was seen in 6 （54.5％）. This result suggests that immunotherapy might be useful for these cases.